Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma.

Abstract:

:Gene array studies on follicular lymphoma (FL) have associated non-malignant tumor-infiltrating immune cells with patient survival. We examined the role of such cells detectable by immunohistochemistry in a tissue microarray, focusing on plasmacytoid dendritic cells (pDCs). These cells physiologically produce interferon-α, which has been used in the therapy of FL. High numbers of pDCs are associated with increased survival, and so are high numbers of CD3+ T cells. The regular distribution of pDCs within T cell areas is reflected by a weak but significant correlation between pDCs and T cells. However, in multivariate Cox models, CD123 proved to be an independent prognostic factor. These findings support the hypothesis of an association of pDCs with better prognosis by producing interferon. Furthermore, due to a linear relationship between pDCs and survival shown by means of Kaplan-Meier plots, immunohistochemical staining of CD123 could serve as a prognostic tool for patients with FL.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Butsch R,Lukas Waelti S,Schaerer S,Braun J,Korol D,Probst-Hensch N,Moch H,Kurrer M

doi

10.3109/10428194.2011.569619

subject

Has Abstract

pub_date

2011-07-01 00:00:00

pages

1230-8

issue

7

eissn

1042-8194

issn

1029-2403

journal_volume

52

pub_type

杂志文章
  • Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.

    abstract::Six patients with Waldenström's macroglobulinemia (WM) resistant to previous 2-chlorodeoxyadenosine (2-CdA) therapy were treated with fludarabine. Both initial and subsequent therapy was administered according to the most widely used protocols. The median number of 2-CdA cycles given to the patients was 3.7 (range 2-5...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290006161

    authors: Lewandowski K,Halaburda K,Hellmann A

    更新日期:2002-02-01 00:00:00

  • Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients.

    abstract::The lung is a relatively rare site for mucosa-associated lymphoid tissue (MALT) lymphomas: we report the largest available single-center series of patients with this presentation. From August 1992 to October 2000, 12 patients with untreated primary low-grade MALT lymphoma of the lung were submitted either to chemother...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000067972

    authors: Zinzani PL,Tani M,Gabriele A,Poletti V,Stefoni V,Alinari L,Musuraca G,Bonifazi F,Pileri S,Tura S,Baccarani M

    更新日期:2003-05-01 00:00:00

  • Angiogenic and lymphangiogenic molecules in hematological malignancies.

    abstract::In this review, the role of angiogenic and lymphangiogenic growth factors in hematological malignancies is summarized, alongside with possible therapeutic applications. Recent data demonstrate the importance of angiogenesis in hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Expression of a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290005964

    authors: Orpana A,Salven P

    更新日期:2002-02-01 00:00:00

  • Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates.

    abstract::We investigated the possibility of immunotherapy for multiple myeloma (MM) using myeloma-specific cytotoxic T lymphocytes (CTLs) that were stimulated in vitro by dendritic cells (DCs) pulsing with purified and optimized myeloma lysates. CD14(+) cells were cultured in the presence of GM-CSF and IL-4. On day 6, the imma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701583975

    authors: Lee JJ,Choi BH,Kang HK,Park MS,Park JS,Kim SK,Pham TN,Cho D,Nam JH,Kim YJ,Rhee JH,Yang DH,Kim YK,Kim HJ,Chung IJ

    更新日期:2007-10-01 00:00:00

  • The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma.

    abstract::Histological transformation of low-grade non-Hodgkin lymphoma (NHL) to diffuse large cell NHL is well recognized and is associated with a poor prognosis. We sought to determine the overall outcome and the factors that affect survival in patients with histological transformation of low-grade NHL. Between November 1979 ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600757894

    authors: Micallef IN,Remstein ED,Ansell SM,Colgan JP,Inwards DJ,Johnston PB,Lewis JT,Markovic SN,Porrata LF,White WL,Witzig TE,Ristow K,Habermann TM

    更新日期:2006-09-01 00:00:00

  • Blastic natural killer (NK)-cell lymphoma: report of an unusual CD4 negative case and review of the CD4 negative neoplasms with blastic features in the literature.

    abstract::Blastic Natural Killer (NK)-cell lymphoma is a relatively new entity which has been recently included in the WHO classification. CD4 expression is observed in most cases of blastic NK-cell lymphomas and has been related with skin tropism. We report an unusual CD4 negative blastic NK-cell lymphoma with primary presenta...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190410001723232

    authors: Argyrakos T,Rontogianni D,Karmiris T,Kapsimali V,Grigoriou E,Tsantekidou M,Naum C,Galani V,Pantelidaki C,Harhalakis N,Nikiforakis E,Kanavaros P

    更新日期:2004-10-01 00:00:00

  • Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V.

    abstract::Mastocytosis comprises a heterogeneous group of disorders characterized by proliferation and accumulation of mast cells in 1 or more organ systems. Mast cell leukemia (MCL) is an extremely rare subtype of mastocytosis in which a leukemic spread of mast cells and a rapid progression of disease is seen. In typical cases...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190412331272695

    authors: Noack F,Sotlar K,Notter M,Thiel E,Valent P,Horny HP

    更新日期:2004-11-01 00:00:00

  • Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older.

    abstract::In the rituximab era, several large studies have suggested that full-dose rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) might be the best treatment for patients with diffuse large B-cell lymphoma (DLBCL) aged 60 years and older. However, it remains unclear whether this is also the c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.600486

    authors: Meguro A,Ozaki K,Sato K,Oh I,Fujiwara S,Hosonuma R,Sasazaki M,Kikuchi Y,Hirata Y,Yamamoto C,Uesawa M,Kobayashi H,Matsu H,Okabe H,Uehara E,Nishikawa A,Tatara R,Hatano K,Yamamoto C,Matsuyama T,Toshima M,Ueda M,O

    更新日期:2012-01-01 00:00:00

  • Increased serum soluble Fas ligand associated with recurrent B-cell non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.

    abstract::Fas-ligand (FasL) is a member of the tumor necrosis factor family and transmits apoptotic cell death signal by binding to its receptor, Fas. FasL is expressed on the cell surface of activated T-cell and natural killer (NK) cell. It has been shown that the FasL can be released from the cell surface by metalloproteinase...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909058494

    authors: Kanda Y,Chiba S,Tanaka Y,Kami M,Saito T,Izutsu K,Asai T,Yuji K,Ogawa S,Honda H,Mitani K,Usuki K,Urabe A,Shirakawa K,Yatomi T,Nakamura N,Yazaki Y,Hirai H

    更新日期:1999-08-01 00:00:00

  • Impact of clinical factors on outcome of leukemia patients with TLS-ERG fusion gene.

    abstract::We report the clinical features and outcome of 22 TLS-ERG+ leukemia patients (20 AML and 2 B-ALL). TLS-ERG was tightly associated with extramedullary disease (EMD), complex chromosome abnormalities, and high risk gene mutations including IKZF1, WT1, TET2, NOTCH2, and PHF6. The 6-month leukemia free survival (LFS) with...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1260124

    authors: Pan J,Zhang Y,Zhao YL,Yang JF,Zhang JP,Liu HX,Wu T,Tong CR

    更新日期:2017-07-01 00:00:00

  • Identification of microRNAs modulated by DNA hypomethylating drugs in extranodal NK/T-cell lymphoma.

    abstract::To identify epigenetically silenced miRNAs and to investigate their influences on predictive target oncogenes in extranodal natural killer/T-cell lymphoma (NKTCL). Decitabine treatment was performed to evaluate methylated miRNAs in NKTCL cells. The relationship between a given miRNA and its target mRNA was validated u...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1654096

    authors: Go H,Jang JY,Kim CW,Huh J,Kim PJ,Jeon YK

    更新日期:2020-01-01 00:00:00

  • Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.

    abstract::We retrospectively analyzed immunosuppression status in 287 newly diagnosed multiple myeloma (MM) patients and assessed the prognostic value of immunoparesis on survival. Deep immunoparesis was defined that one of uninvolved immunoglobulins was below 50% the lower limit of normal ranges, partial immunoparesis was defi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1855345

    authors: Geng C,Yang G,Wang H,Wu Y,Leng Y,Zhou H,Zhang Z,Jian Y,Chen W

    更新日期:2020-12-04 00:00:00

  • Statins induce lethal effects in acute myeloblastic leukemia [corrected] cells within 72 hours.

    abstract::HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy. We therefore wished to determine whether short exposures to lovastatin might i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701760011

    authors: Burke LP,Kukoly CA

    更新日期:2008-02-01 00:00:00

  • The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells.

    abstract::Acute myeloid leukemia (AML) is a clonal malignant disease characterized by an increasing number of immature myeloid cells arrested at various stages of granulocytic and monocytic differentiation. The stage of the blockage defines distinct AML subtypes (AML1 to AML5 are the most frequent ones). There is increasing evi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819042000206687

    authors: Gadhoum Z,Delaunay J,Maquarre E,Durand L,Lancereaux V,Qi J,Robert-Lezenes J,Chomienne C,Smadja-Joffe F

    更新日期:2004-08-01 00:00:00

  • [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.

    abstract::Positron emission tomography (PET) after induction therapy in follicular lymphoma (FL) is predictive of survival in clinical trials. We describe use of PET and computed tomography (CT) after rituximab-based induction therapy in FL patients followed by the National LymphoCare Study and explore the association between i...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1213824

    authors: Wong-Sefidan I,Byrtek M,Zhou X,Friedberg JW,Flowers CR,Zelenetz AD,Dawson KL,Reid E

    更新日期:2017-04-01 00:00:00

  • Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.

    abstract::There are limited effective therapies for most patients with relapsed diffuse large B-cell lymphoma (DLBCL). We conducted a phase II trial of the multi-targeted vascular endothelial growth factor receptor (VEGFR) kinase inhibitor, sunitinib, 37.5 mg given orally once daily in adult patients with relapsed or refractory...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2011.555892

    authors: Buckstein R,Kuruvilla J,Chua N,Lee C,Macdonald DA,Al-Tourah AJ,Foo AH,Walsh W,Ivy SP,Crump M,Eisenhauer EA

    更新日期:2011-05-01 00:00:00

  • Preferential expression of phosphatidylglucoside along neutrophil differentiation pathway.

    abstract::Phosphatidylglucoside (PtdGlc), a new type of glycolipid, was recently identified. We examined PtdGlc expression in normal blood cells and leukemic cells using an anti-PtdGlc monoclonal antibody, DIM-21. Neutrophils, monocytes, HL-60 cells and a subset of cord blood (CB) CD34(+) cells, but not erythroblasts, expressed...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190902934928

    authors: Oka S,Nagatsuka Y,Kikuchi J,Yokote T,Hirabayashi Y,Hanafusa T,Ozawa K,Muroi K

    更新日期:2009-07-01 00:00:00

  • Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis.

    abstract::JAK inhibitors for myelofibrosis (MF) reduce spleen size, control constitutional symptoms, and may improve survival. We studied the clinical characteristics of 548 MF patients treated with JAK inhibitors from 2008 to 2016 to better understand predictors of splenic response. Response was defined as a 50% decrease in sp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1509315

    authors: Menghrajani K,Boonstra PS,Mercer JA,Perkins C,Gowin KL,Weber AA,Mesa R,Gotlib JR,Wang L,Singer JW,Talpaz M

    更新日期:2019-04-01 00:00:00

  • T-cell and NK/T-cell lymphomas in southern Taiwan: a study of 72 cases in a single institute.

    abstract::In an attempt to better understand the clinicopathologic features of T- and natural killer (NK)/T-cell lymphomas in Taiwan and the distribution and relative frequency of each subtype according to the new WHO classification, the pathology file of a medical center in southern Taiwan during 1989-2002 was retrospectively ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001625881

    authors: Lu D,Lin CN,Chuang SS,Hwang WS,Huang WT

    更新日期:2004-05-01 00:00:00

  • Monocytic myeloid-derived suppressor cells in chronic lymphocytic leukemia patients: a single center experience.

    abstract::This study aimed to analyze the frequency of peripheral Mo-myeloid-derived suppressor cells (Mo-MDSCs) in newly diagnosed CLL patients and to correlate their level with other prognostic factors such as frequency of CD38 cells and ZAP-70 cells and with the clinical response and survival outcomes in these patients. Fift...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1728747

    authors: Zahran AM,Moeen SM,Thabet AF,Rayan A,Abdel-Rahim MH,Mohamed WMY,Hetta HF

    更新日期:2020-07-01 00:00:00

  • Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.

    abstract::Preclinical studies suggest that bortezomib, through inhibition of nuclear factor-κB (NF-κB) activation, may enhance the effects of radioimmunotherapy. This phase I trial was designed to determine the maximum tolerated dose (MTD) of weekly bortezomib induction combined with Y-90-ibritumomab tiuxetan followed at the ti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.722215

    authors: Roy R,Evens AM,Patton D,Gallot L,Larson A,Rademaker A,Cilley J,Spies S,Variakojis D,Gordon LI,Winter JN

    更新日期:2013-03-01 00:00:00

  • Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF).

    abstract::The aim of the present study was to evaluate the efficacy of the combination of fludarabine 30/mg/m2 + cytarabine 2g/m2 followed by the administration of G-CSF to achieve a complete remission (CR) in patients with relapsed acute lymphoblastic leukemia (ALL). We treated twelve patients in first relapse, overall 10 pati...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199709039047

    authors: Montillo M,Tedeschi A,Centurioni R,Leoni P

    更新日期:1997-05-01 00:00:00

  • Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

    abstract::Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disrupting cell-cell interac...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2018.1457147

    authors: Pleyer C,Wiestner A,Sun C

    更新日期:2018-12-01 00:00:00

  • Acute myelogenous leukemia associated with a mediastinal tumor.

    abstract::We describe a 45-year-old female who developed acute myelogenous leukemia (AML) associated with a mediastinal mass. The patient achieved a complete remission accompanied by resolution of the mediastinal mass following intensive chemotherapy alone. A review of the literature disclosed ten AML patients with a mediastina...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309059583

    authors: Chubachi A,Miura I,Takahashi N,Nimura T,Imai H,Miura AB

    更新日期:1993-12-01 00:00:00

  • The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease.

    abstract::We have recently shown that the lysosomotropic amine, chloroquine, can inhibit the development of graft-versus-host disease (GVHD) secondary to minor histocompatibility (MiHC) differences in mice. In addition, we have shown that both chloroquine and hydroxychloroquine can inhibit T cell responses in vitro to minor and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709039008

    authors: Schultz KR,Gilman AL

    更新日期:1997-01-01 00:00:00

  • Gastric stump lymphoma five years after distal gastrectomy.

    abstract::We report the case of a 77-year-old man who developed low grade B cell non-Hodgkin's lymphoma of the gastric stump 5 years after undergoing a distal gastrectomy for benign gastric ulcer. Lymphoma occurring in the post-operative stomach would appear to be very rare, with only 14 previously recorded cases. The median pe...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000050034

    authors: Di Cosimo S,Ferretti G,Partenzi A,Manicone AM,D'Aprile M

    更新日期:2003-02-01 00:00:00

  • Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation.

    abstract::The ubiquitin-proteasome-dependent proteolytic system has been reported to regulate apoptotic cell death in many experimental cell models. We recently found that B-CLL (chronic lymphocytic leukemia) lymphocytes are hypersensitive to apoptotic death activation through specific inhibition of proteasome function by lacta...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190009059268

    authors: Masdehors P,Merle-Béral H,Magdelénat H,Delic J

    更新日期:2000-08-01 00:00:00

  • An unusual case of composite lymphoma involving chronic lymphocytic leukemia follicular lymphoma and Hodgkin disease.

    abstract::Composite lymphomas constitute the presence of two different types of non-Hodgkin lymphoma or Hodgkin and non-Hodgkin lymphoma at the same anatomic site. We report an unusual case of a 73-year-old woman who initially presented with a composite lymphoma of chronic lymphocytic leukemia (CLL) and follicular lymphoma. Aft...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819032000159870

    authors: Copur MS,Ledakis P,Novinski D,Fu K,Hutchins M,Frankforter S,Mleczko K,Sanger WG,Chan WC

    更新日期:2004-05-01 00:00:00

  • Effects of parathyroid hormone-related protein and macrophage inflammatory protein-1α in Jurkat T-cells on tumor formation in vivo and expression of apoptosis regulatory genes in vitro.

    abstract::Parathyroid hormone-related protein (PTHrP) and macrophage inflammatory protein-1α (MIP-1α) have been implicated in the pathogenesis of adult T-cell leukemia/lymphoma, but their effects on T-cells have not been well studied. Here we analyzed the functions of PTHrP and MIP-1α on T-cell growth and death both in vitro an...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.626883

    authors: Shu ST,Dirksen WP,Lanigan LG,Martin CK,Thudi NK,Werbeck JL,Fernandez SA,Hildreth BE 3rd,Rosol TJ

    更新日期:2012-04-01 00:00:00

  • Initial therapy for acute myeloid leukemia in older patients: principles of care.

    abstract::Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. The receipt of chemotherapy or hematopoietic cell transplantation is ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1323275

    authors: Bhatt VR,Gundabolu K,Koll T,Maness LJ

    更新日期:2018-01-01 00:00:00